Monitor for subsequent VA procurement contracts or volume-based purchase orders from AvMEDICAL as the next concrete catalyst; this filing is a marketing event with no binding commercial commitment.
Price Chart
Executive Summary
bioAffinity Technologies announced it debuted its CyPath Lung test alongside distribution partner AvMEDICAL at the NAVREF Annual Conference, reaching over 300 VA physicians and administrators. The filing is a routine business development update with no financial data or material commercial commitments disclosed.
Key Facts
- First joint exhibition of CyPath Lung under distribution agreement with AvMEDICAL at NAVREF Annual Conference in Arlington, Virginia
- Event reached more than 300 physicians, healthcare professionals and VA leaders
- bioAffinity also presented CyPath Lung at the GO2 for Lung Cancer Centers of Excellence conference in San Diego
- No financial terms, revenue guidance, or material contractual milestones disclosed
Financial Impact
No financial figures provided in the filing
Risk Factors
- Distribution agreement may not convert into meaningful government contract revenue
- Company's need for additional capital as noted in forward-looking statements
- Competition from other lung cancer diagnostic technologies
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045034 |
| Exhibit: ex99-1.htm | 0001493152-26-045034 |
| Document: 0001493152-26-045034-index-headers.html | 0001493152-26-045034 |
| Document: 0001493152-26-045034-index.html | 0001493152-26-045034 |
| Document: 0001493152-26-045034.txt | 0001493152-26-045034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers